Krystal Biotech, Inc.
KRYSAPI behind this page
KRYS Q1 2026 request
Playground key active
/api/financials?ticker=KRYS&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 116,357 | 88,183 | +31.9% |
Show Geography breakouts |
|||
| Europe | 20,677 | — | — |
| JP | 8,191 | — | — |
| US | 87,489 | 88,183 | -0.8% |
| Cost Of Goods And Services Sold Operating | 6,323 | 5,028 | +25.8% |
| Research & Development | 15,331 | 14,256 | +7.5% |
Show Business Segments breakouts |
|||
| Reportable Segment | 15,331 | 14,256 | +7.5% |
| Reportable Segment · B-VEC | 547 | 1,973 | -72.3% |
| Reportable Segment · KB111 | 992 | 27 | +3574.1% |
| Reportable Segment · KB304 | 3 | 242 | -98.8% |
| Reportable Segment · KB407 | 762 | 349 | +118.3% |
| Reportable Segment · KB408 | 143 | 298 | -52.0% |
| Reportable Segment · KB707 | 2,432 | 2,738 | -11.2% |
| Reportable Segment · KB801 | 787 | 454 | +73.3% |
| Reportable Segment · KB803 | 1,142 | 486 | +135.0% |
| Reportable Segment · Other research and development costs | 7,787 | 6,997 | +11.3% |
| Reportable Segment · Other research programs | 736 | 692 | +6.4% |
| Selling, General & Administrative | 41,014 | 32,647 | +25.6% |
Show Business Segments breakouts |
|||
| Reportable Segment | 41,014 | 32,647 | +25.6% |
| Operating Expenses | 62,668 | 51,931 | +20.7% |
| Operating Income | 53,689 | 36,252 | +48.1% |
Show Business Segments breakouts |
|||
| Reportable Segment | 53,689 | 36,252 | +48.1% |
| Interest Income Expense Nonoperating Net | 7,753 | 7,345 | +5.6% |
Show Business Segments breakouts |
|||
| Reportable Segment | 7,753 | 7,345 | +5.6% |
| Income Before Taxes | 61,442 | 43,597 | +40.9% |
Show Business Segments breakouts |
|||
| Reportable Segment | 61,442 | 43,597 | +40.9% |
| Income Tax Expense (Benefit) | -5,510 | -7,864 | +29.9% |
Show Business Segments breakouts |
|||
| Reportable Segment | -5,510 | -7,864 | +29.9% |
| Net Income | 55,932 | 35,733 | +56.5% |
Show Business Segments breakouts |
|||
| Reportable Segment | 55,932 | 35,733 | +56.5% |
Show Equity Components breakouts |
|||
| Retained Earnings | 55,932 | 35,733 | +56.5% |
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | -1,577 | 344 | -558.4% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -1,577 | 344 | -558.4% |
| Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | -1,182 | 236 | -600.8% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -1,182 | 236 | -600.8% |
| Comprehensive Income | 53,173 | 36,313 | +46.4% |
| EPS (Basic) | 1.91 | 1.24 | +54.0% |
| EPS (Diluted) | 1.83 | 1.2 | +52.5% |
| Wtd Avg Shares (Basic) | 29,288 | 28,815 | +1.6% |
| Wtd Avg Shares (Diluted) | 30,507 | 29,871 | +2.1% |
| Professional Fees (Q) | — | — | — |
Show Supply Commitment breakouts |
|||
| Clinical Supply Agreements | 2.5 | 2.2 | +13.6% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 501,313 | — | — |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level1 · Cash | 501,313 | — | — |
| Available For Sale Securities Debt Securities Current | 322,092 | 308,076 | +4.5% |
| Accounts Receivable | 127,022 | 103,260 | +23.0% |
| Inventory | 42,646 | — | — |
| Prepaid Taxes | 10,642 | — | — |
| Prepaid Expenses & Other Current Assets | 16,026 | 16,750 | -4.3% |
| Total Current Assets | 1,019,741 | 766,798 | +33.0% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 153,582 | 151,070 | +1.7% |
| Long Term Investments | 193,485 | 148,472 | +30.3% |
| Operating Lease Right-of-Use Assets | 7,035 | 7,858 | -10.5% |
| Deferred Tax Assets | 22,824 | — | — |
| Other Non-Current Assets | 300 | 218 | +37.6% |
| Total Assets | 1,396,967 | 1,074,416 | +30.0% |
| Current Liabilities | |||
| Accounts Payable | 4,089 | 2,672 | +53.0% |
| Operating Lease Liability Current | 1,800 | 1,362 | +32.2% |
| Accrued Rebates Current | 70,717 | 47,405 | +49.2% |
| Accounts Payable And Other Accrued Liabilities Current | 31,196 | 28,050 | +11.2% |
| Total Current Liabilities | 107,802 | 79,489 | +35.6% |
| Non-Current Liabilities | |||
| Operating Lease Liabilities | 7,312 | 8,300 | -11.9% |
| Other Non-Current Liabilities | 5,124 | 1,953 | +162.4% |
| Total Liabilities | 120,238 | 89,742 | +34.0% |
| Stockholders' Equity | |||
| Additional Paid-In Capital | 1,198,257 | 1,129,219 | +6.1% |
| Accumulated Other Comprehensive Income | -1,623 | 390 | -516.2% |
| Retained Earnings | 80,095 | — | — |
| Total Stockholders' Equity | 1,276,729 | 984,674 | +29.7% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -1,623 | 390 | -516.2% |
| Additional Paid In Capital | 1,198,257 | 1,129,219 | +6.1% |
| Retained Earnings | 80,095 | -144,935 | +155.3% |
| Total Liabilities & Equity | 1,396,967 | 1,074,416 | +30.0% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation | 1,522 | 1,410 | +7.9% |
| Accretion Expense Net | -576 | -453 | -27.2% |
| Operating Lease Right Of Use Asset Amortization Expense | 204 | 224 | -8.9% |
| Stock-Based Compensation | 13,609 | 13,478 | +1.0% |
| Realized Investment Gains Losses | -529 | -1,502 | +64.8% |
| Other Operating Activities Cash Flow Statement | 136 | 614 | -77.9% |
| Change in Accounts Receivable | 58 | 1,486 | -96.1% |
| Change in Inventory | -243 | -1,395 | +82.6% |
| Increase Decrease In Prepaid Taxes | 3,365 | 457 | +636.3% |
| Change in Prepaid & Other Assets | -1,699 | -3,433 | +50.5% |
| Increase Decrease In Lease Liability | -227 | -136 | -66.9% |
| Change in Other Liabilities | 1,435 | 534 | +168.7% |
| Change in Accounts Payable | 1,022 | 906 | +12.8% |
| Increase Decrease In Accrued Rebates | 12,685 | 10,601 | +19.7% |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | -6,312 | 3,695 | -270.8% |
| Net Cash from Operations | 80,382 | 30,969 | +159.6% |
| Investing Activities | |||
| Capital Expenditures | -7,148 | -6,204 | -15.2% |
| Payments To Acquire Investments | -160,033 | -137,806 | -16.1% |
| Proceeds From Sale Maturity And Collection Of Shortterm Investments | 103,598 | 88,806 | +16.7% |
| Net Cash from Investing | -63,583 | -54,769 | -16.1% |
| Financing Activities | |||
| Proceeds From Stock Options Exercised | 6,501 | 1,462 | +344.7% |
| Tax Withholding for Share Compensation (Q) | — | — | — |
Show Award Type breakouts |
|||
| Restricted Stock Units RSU | -16,960 | -12,116 | -40.0% |
| Net Cash from Financing | -10,459 | -12,466 | +16.1% |
| Supplemental | |||
| Unpaid Capital Expenditures | 1,218 | 1,397 | -12.8% |
| Income Taxes Paid | 627 | 400 | +56.8% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -1,331 | 171 | -878.4% |
| Net Change in Cash | 5,009 | -36,095 | +113.9% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 501,313 | 308,770 | +62.4% |
Values in thousands USD. Source: SEC EDGAR 10-Q filing.